rs4253623 — PPARA

PPARA's Intronic Regulator — A Modest Modifier of Cardiovascular Inflammation Risk

PPARA¹¹ PPARA
Peroxisome Proliferator-Activated Receptor Alpha — a nuclear receptor that functions as a master regulator of fatty acid oxidation, lipoprotein metabolism, and vascular inflammation is the molecular target of fibrate drugs and one of the most studied transcription factors in cardiovascular biology. When activated by fatty acids or fibrates, PPARα binds DNA and switches on hundreds of genes controlling fat burning in the liver, heart, and vascular wall — while simultaneously silencing inflammatory genes through a process called transrepression²² transrepression
PPARα binds pro-inflammatory transcription factors like NF-κB and AP-1 and prevents them from activating cytokine genes. The rs4253623 variant sits in an intron of PPARA on chromosome 22, where it may subtly alter the gene's transcriptional output without changing the receptor protein itself.

The Mechanism

rs4253623 is classified as an intron variant in PPARA — it does not change any amino acid in the PPARα receptor protein. Like many intronic regulatory polymorphisms, it likely exerts its effects through changes to splicing enhancer sequences, intronic regulatory elements, or mRNA stability that modulate how much functional PPARα is produced in vascular tissues and the liver. The PPARA gene on chromosome 22q13 contains multiple intronic regulatory regions that respond to metabolic signals; subtle changes in these elements can shift the balance between PPARα's fat-burning and anti-inflammatory activities.

The G allele is the minor allele³³ minor allele
less common variant, present in about 13% of people globally and has been associated with higher myocardial infarction risk in the one published cardiovascular study. This is consistent with a scenario in which the G allele modestly reduces PPARα transcriptional activity in the heart or coronary vasculature — impairing both lipid catabolism and anti-inflammatory transrepression, the two PPARα mechanisms most relevant to atherosclerosis. However, no direct functional studies have characterized the molecular effect of this specific intronic variant on PPARα expression or activity.

The Evidence

The primary cardiovascular evidence comes from a population-based case-control study of incident cardiovascular events⁴⁴ population-based case-control study of incident cardiovascular events
Enquobahrie DA et al. Cholesterol ester transfer protein, interleukin-8, peroxisome proliferator activator receptor alpha, and Toll-like receptor 4 genetic variations and risk of incident nonfatal MI and ischemic stroke. Am J Cardiol, 2008 that enrolled 848 nonfatal MI patients, 368 ischemic stroke patients, and 2,682 controls from Group Health in western Washington. The G allele of rs4253623 was associated with a higher risk of MI (OR 1.25, 95% CI 1.08–1.46) in an additive model. No significant association was found for ischemic stroke. The investigators noted that this was a novel finding requiring independent replication. No replication study has been published to date.

A separate haplotype study of PPARA variants in acute high-altitude exposure⁵⁵ haplotype study of PPARA variants in acute high-altitude exposure
Yang J et al. Mol Genet Genomic Med, 2019 in 151 young Chinese men found that a four-SNP PPARA haplotype including the rs4253623 A-allele was associated with a 7.27-fold risk of cardiac pumping function reduction at 3,700 m altitude. Because rs4253623 A is the common/reference allele, this haplotype finding does not add to the case that G is a risk allele for ordinary cardiovascular outcomes — it reflects a different biological context.

A Chinese Han study of six PPARA SNPs and CRP levels⁶⁶ Chinese Han study of six PPARA SNPs and CRP levels
Zhang et al. Arch Iran Med, 2015 in 1,260 adults found that rs4253623 was not significantly associated with C-reactive protein levels before or after covariate adjustment, suggesting this variant does not strongly influence basal inflammatory set point via CRP — the relevant pathway for the rs1800206 (L162V) variant in the same gene.

Two Chinese periodontitis studies found the G allele protective against generalized aggressive periodontitis (OR 1.53 for the A allele; G protective), consistent with PPARα's known anti-inflammatory role in periodontal tissue. This directional conflict with the cardiovascular MI data is not unusual: the same allele can reduce risk in one tissue context while increasing risk in another through differing local PPARα expression patterns.

Practical Implications

The evidence base for rs4253623 is limited to one cardiovascular association study and a handful of single-disease studies, none of which have been replicated for cardiovascular outcomes. The OR 1.25 for MI in G-allele carriers is modest and has not reached the evidence threshold for clinical practice guidelines. This variant should be interpreted in the context of the broader PPARA gene, where the well-studied coding variant rs1800206 (L162V) and the exercise-relevant intron 7 variant (rs4253778) have more extensive evidence bases.

Given PPARα's established role as a target of fibrate drugs for hypertriglyceridemia and mixed dyslipidemia, the most relevant modifiable factor for carriers of the G allele is maintaining a lipid-favorable diet with adequate omega-3 fatty acids — which activate PPARα directly and may compensate for reduced intrinsic PPARα activity.

Interactions

rs4253623 is located in the same gene as two better-characterized PPARA variants: rs4253778 (intron 7, the exercise and cardiac remodeling variant) and rs1800206 (Leu162Val, the fibrate-response coding variant). These variants are not in strong linkage disequilibrium and represent independent functional signals within PPARA. The Zhang et al. study found that only rs1800206 significantly associated with CRP in Chinese Han subjects, confirming that rs4253623 and rs1800206 capture distinct aspects of PPARα biology.

Variants in PPARA interact with dietary fat composition — omega-3 fatty acids (EPA and DHA) are endogenous PPARα ligands that activate the receptor irrespective of genotype and may partially compensate for reduced intrinsic PPARα activity.